Parnassus evaluates the pricing structure of any pharmaceutical company under consideration for our portfolios. In this issue of Principles and Performance®, we focus on manufacturers’ drug pricing models, while recognizing that this is only one of many issues affecting the affordability and quality of medicine.
One important aspect of Parnassus’s ongoing ESG research and monitoring is encouraging positive change in portfolio companies through shareholder engagement. Read more in this month’s Principles and Performance®.
In the face of potential rollbacks on ESG issues with the incoming administration, Parnassus Investments remains
committed to delivering both Principles and Performance®.
In this month’s issue, Parnassus Investments has collected resources you can use to learn more about the environmental, social and governance topics we’ve touched on in Principles and Performance® during 2016.
In this month’s Principles and Performance®, we feature highlights from a new paper on issues related to water management. CIO Todd C. Ahlsten discusses two investments held by Parnassus Investments that are relevant to this compelling environmental topic.